Preview

Aterotromboz = Atherothrombosis

Advanced search

HOW TO CREATE A LABORATORY EXAMINATION PROGRAM FOR A PATIENT WITH BLOOD-CLOTTING DISORDERS

https://doi.org/10.21518/2307-1109-2017-2-95-108

Abstract

Impairments in haemostatic system function may result in the clinical manifestations in the form of haemorrhagic and/or thrombotic episodes and their combinations. Such cases are widespread in clinical practice, and a physician across specialties may face them. The creation of a laboratory examination program at the initial stage and in the follow-up of a patient depends on the clinical situation and working hypothesis, on the involvement of various mechanisms of the haemostasis system. Screening tests are the basis of the initial examination algorithms for the patient. Additional tests are added based on the initial examination results, clinical picture and medical history data. It is necessary to understand the essence of the performed examinations, their characteristics and the areas of responsibility of each in order to effectively use modern laboratory diagnostic capabilities. The most important clinical decisions can be made on the basis of the lab examination results — from establishing diagnosis to identifying the risks of recurrent thrombotic or haemorrhagic events and creating an appropriate secondary prevention program and choice of therapies, lifestyle changes, pregnancy planning and contraceptive methods.

About the Author

T. V. VAVILOVA
Almazov National Medical Research Center of the Ministry of Health of Russia
Russian Federation
MD, Prof.


References

1. Бокарев И.Н. с соавт. Лабораторные методы исследования системы свертывания крови. Методические рекомендации Ассоциации по тромбозам, гемостазу и патологии сосудистой стенки им. А.А. Шмидта — Б.А. Кудряшова. М., 2012. 48 с.

2. Грашин Р.А., Вавилова Т.В. Программы и алгоритмы наиболее часто встречающихся нарушений гемостаза. В кн.: Медицинская лабораторная диагностика: программы и алгоритмы. Пособие для врачей под редакцией проф. А.И. Карпищенко. М.: ГЭОТАР-Медиа, 2014: 517-564.

3. Гильманов А.Ж., Вавилова Т.В., Мамаев А.Н. Коагулологические исследования. В кн.: Национальное руководство. Клиническая лабораторная диагностика: национальное руководство: в 2 т. Т. 1. Под ред. В.В. Долгова, В.В. Меньшикова. М.: ГЭОТАР-Медиа, 2012: 749-815.

4. Сироткина О.В., Гайковая Л.Б., Кухарчик Г.А., Шабров А.В. Способ оценки эффективности действия антиагрегантных препаратов, влияющих на метаболизм арахидоновой кислоты путем ингибирования циклооксигеназы-1 как в отдельности, так и совместно с антагонистом рецептора АДФ Р2Y12 на тромбоцитарных мембранах, на состояние тромбоцитов крови пациента, принимающего антиагрегантные препараты указанной группы. Патент на изобретение №2442167, бюллетень №4 от 10.02.2012.

5. Taylor FB Jr et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis Haemost, 2001, Nov, 86(5): 1327-30.

6. Sorensen B, Ingerslev J. Dynamic APTT parameters: applications in thrombophilia. Journal of Thrombosis and Haemostasis, 2012, 10: 244-50.

7. Khoury T, Ayman AR, Cohen J, Daher S, Shmuel C, Mizrahi M. The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going. Digestion, 2016, 93: 149–159.

8. Kearon C et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report, 2016, 149(2): 315-352.

9. Stevens S.M. et al Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thrombosis Thrombolysis, 2016, 41: 154-164.

10. Кропачева Е.С. с соавт. Исследование фармакогенетики варфарина и клопидогрела для оптимизации антитромботической терапии. Пособие для врачей. М., 2015. 71 с.


Review

For citations:


VAVILOVA T.V. HOW TO CREATE A LABORATORY EXAMINATION PROGRAM FOR A PATIENT WITH BLOOD-CLOTTING DISORDERS. Aterotromboz = Atherothrombosis. 2017;(2):95-108. (In Russ.) https://doi.org/10.21518/2307-1109-2017-2-95-108

Views: 972


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)